Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Licenses Stroke Biomarkers to Undisclosed Dx Firm

NEW YORK, June 29 (GenomeWeb News) - Proteome Sciences licensed its stroke biomarkers to "one of the top 10 global leaders in clinical diagnostics," the company said yesterday.


Under the research license, a number of Proteome Sciences biomarkers will be tested inclusion in a new panel for a high-throughput diagnostic platform. After incorporating the stroke markers, the licensee will develop an HTS stroke test, Proteome Sciences said in a statement.


The licensee declined to be identified by Proteome Sciences, citing competitive reasons. Proteome Sciences did say this is a new area for the licensee.


No financial details were disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.